Loading
A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia is a phase 2 interventional study registered as NCT05384587 by Novartis Pharmaceuticals, with 34 participants enrolled, started 2022-11-11 and due to reach its primary completion in 2025-08-13. Interventions recorded: asciminib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML), Novartis and the tag pipeline.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/